database > company
Agennix
Biotech Specialty Pharma
8 Greenway Plaza, Suite 910
Houston, TX 77046 USA
phone:(713) 552-1091
fax:(713) 552-0795
Symbol Private
Founded 0
Employees
          www.agennix.com
Research Sector Biotech Specialty Pharma
Summary Description
Protein-based drugs for cancer and diabetic ulcers.
Management
Rick G. Barsky, Chief Executive Officer; Rajesh Malik, M.D., Chief Medical Officer; Karel Petrak, Ph.D., Vice President of Research & Development; Atul Varadhachary, M.D., Ph.D., President and Chief Operating Officer;John Schaumberg, Ph.D., Senior Vice-President, Clinical Operations; Yenyun Wang, M.D., Executive Director, Clinical Development; Gordon A. Cain, Founding Chairman, Agennix; Frank Young, M.D., Ph.D., Chairman of the Board, Agennix; Rick G. Barsky, Chief Executive Officer, Agennix; Rob van Leen, Ph.D., Chief Innovation Officer, DSM; Atul Varadhachary, M.D., Ph.D., President and Chief Operating Officer, Agennix; James Weaver, President, Gordon and Mary Cain Foundation
Keywords
woundwound, woundcare

Comment | Printable Version | Modify profile Feb. 06, 2009

Description
Agennix is focused on developing protein-based drugs for cancer and diabetic ulcers.
Products / Services
The company's lead molecule, Talactoferrin Alfa, is an immunomodulatory protein. Agennix is currently preparing to initiate Phase III development of oral talactoferrin for cancer, and topical talactoferrin gel for wound healing. Liquid talactoferrin is an oral anti-cancer drug that has shown activity both as monotherapy and in combination with other chemotherapeutic agents


2010-09-06-998